

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,657	91.6%	20,368	92.2%	2,027	88.0%	1,986	90.8%	133	89.9%	3,037	87.2%
Epidermoid carcinoma ^d (8051-8131)	195	0.7%	154	0.7%	18	0.8%	21	1.0%	-	-	34	1.0%
Adenocarcinoma ^e	22,673	84.2%	18,826	85.2%	1,761	76.5%	1,838	84.0%	120	81.1%	2,749	78.9%
Adenocarcinoma, NOS (8140)	3,016	11.2%	2,435	11.0%	380	16.5%	169	7.7%	16	10.8%	322	9.2%
Papillary adenocarcinoma, NOS (8050,8260)	300	1.1%	249	1.1%	34	1.5%	-	-	-	-	40	1.1%
Clear cell adenocarcinoma (8310,9110)	1,449	5.4%	1,097	5.0%	67	2.9%	271	12.4%	-	-	159	4.6%
Endometrioid carcinoma (8380-8383,8570)	2,665	9.9%	2,202	10.0%	133	5.8%	302	13.8%	-	-	406	11.7%
Cystadenocarcinoma, NOS (8440,8450)	76	0.3%	59	0.3%	-	-	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	7,000	26.0%	5,936	26.9%	509	22.1%	467	21.4%	48	32.4%	746	21.4%
Papillary serous cystadenocarcinoma (8460-8462)	5,360	19.9%	4,563	20.6%	434	18.8%	320	14.6%	24	16.2%	662	19.0%
Mucinous cystadenocarcinoma (8470-8473)	356	1.3%	283	1.3%	23	1.0%	46	2.1%	-	-	50	1.4%
Mucinous adenocarcinoma (8480,8482)	999	3.7%	783	3.5%	85	3.7%	112	5.1%	-	-	144	4.1%
Mucin-producing adenocarcinoma(8481)	31	0.1%	23	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,421	5.3%	1,196	5.4%	82	3.6%	130	5.9%	-	-	204	5.9%
Other specific carcinomas ^g	640	2.4%	454	2.1%	132	5.7%	42	1.9%	-	-	103	3.0%
Stromal cell tumor (8620-8631,8650)	453	1.7%	309	1.4%	107	4.6%	26	1.2%	-	-	76	2.2%
Other ^h	187	0.7%	145	0.7%	25	1.1%	16	0.7%	-	-	27	0.8%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,149	4.3%	934	4.2%	116	5.0%	85	3.9%	-	-	151	4.3%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013

Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	86	0.3%	58	0.3%	18	0.8%	-	-	-	-	19	0.5%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,867	6.9%	1,439	6.5%	213	9.2%	175	8.0%	-	-	385	11.1%
Mullerian mixed tumor (8950-8951,8980)	828	3.1%	701	3.2%	66	2.9%	48	2.2%	-	-	87	2.5%
Teratoma, malignant (9080-9085,9102)	414	1.5%	274	1.2%	65	2.8%	59	2.7%	-	-	150	4.3%
Other	625	2.3%	464	2.1%	82	3.6%	68	3.1%	-	-	148	4.3%
Unspecified (8000-8005)	303	1.1%	232	1.0%	45	2.0%	18	0.8%	-	-	41	1.2%
Total ^d	26,913	100.0%	22,097	100.0%	2,303	100.0%	2,187	100.0%	148	100.0%	3,482	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.